{"grounding": "Sickle cell disease (SCD) is a monogenic blood disease caused by a point mutation in the gene coding for \u03b2-globin. The abnormal hemoglobin [sickle hemoglobin (HbS)] polymerizes under low-oxygen conditions and causes red blood cells to sickle. The clinical presentation varies from very severe (with acute pain, chronic pain, and early mortality) to normal (few complications and a normal life span). The variability of SCD might be due (in part) to various genetic modulators. First, we review the main genetic factors, polymorphisms, and modifier genes that influence the expression of globin or otherwise modulate the severity of SCD. Considering SCD as a complex, multifactorial disorder is important for the development of appropriate pharmacological and genetic treatments. Second, we review the characteristics, advantages, and disadvantages of the latest advances in gene therapy for SCD, from lentiviral-vector-based approaches to gene-editing strategies.", "generated_text": "Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by the presence of sickle-shaped red blood cells, leading to severe clinical complications. Recent advances in understanding the genetic modifiers of SCD have paved the way for innovative therapeutic strategies. This review explores the role of genetic modifiers in disease severity and the promising curative approaches, including gene therapy and gene editing. Gene therapy trials utilizing viral vectors have shown potential in correcting the defective hemoglobin gene, although concerns about genotoxicity remain. Gene editing technologies, such as CRISPR/Cas9, offer precise genome modifications, presenting a potential cure for SCD. However, challenges such as off-target effects and delivery mechanisms need to be addressed. This paper highlights the progress in genetic research and therapeutic interventions, emphasizing the need for continued exploration to achieve safe and effective cures for SCD.", "label": 1}